Advances in Molecular Therapies in Patients with Brain Tumors (Q35113656)

6 August 2017

1 reference

title

Advances in molecular therapies in patients with brain tumors (English)

1 reference

6 August 2017

Advances in Molecular Therapies in Patients with Brain Tumors (English)

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

author name string

Ivo W. Tremont-Lukats

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:12712007

27 December 2023

Mark R. Gilbert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:12712007

27 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12712007

27 December 2023

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

125-137

1 reference

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Gliomagenesis: genetic alterations and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

PTEN gene and integrin signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Selected novel anticancer treatments targeting cell signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

STI571: targeting BCR-ABL as therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Protein kinase A as target for novel integrated strategies of cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839 (IRESSA): a selective EGFR-TK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Evolving therapies: farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Novel targets for lung cancer therapy: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Rapamycin's resurrection: a new way to target the cancer cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten /- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Influence of a novel rapamycin analogon SDZ RAD on endothelial tissue factor and adhesion molecule expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Angiogenesis inhibitors in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Genes that regulate metastasis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

The adaptor protein Shc couples a class of integrins to the control of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide: current and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Temozolomide for advanced, metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Anti-angiogenic treatment strategies for malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

A review of current and future treatment strategies for malignant astrocytomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide: an antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Theoretical basis for the activity of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide in cancer treatment: a potential role in the elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Angiogenesis inhibitors in clinical development for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

The endothelin system in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effects of extracellular Ca2 influx on endothelin-1-induced intracellular mitogenic cascades in C6 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Endothelin-1 induces intracellular calcium rise and inositol 1,4,5-trisphosphate formation in cultured rat and human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Diacylglycerol formation and DNA synthesis in endothelin-stimulated rat C6 glioma cells: the possible role of phosphatidylcholine breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Functional endothelin-1 receptors in rat astrocytoma C6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Matrix metalloproteinase inhibitors: Present achievements and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Preclinical and clinical studies of MMP inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Clinical potential of matrix metalloprotease inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Ongoing trials with matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Proteasome inhibition in cancer: development of PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Proteasome inhibition: a novel approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Molecular pathways that modify tumor radiation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Arachidonic acid metabolism in cultured astrocytes from rat embryo and in C6 glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

21 January 2018

13

60

5143

Kilic T.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

24

61

6500

Albanell J.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

27 December 2023

36

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

45

61

1527

Geoerger B.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

27 December 2023

52

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

SDZ RAD. Rapamycin SDZ

55

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Farnesylated proteins and cell cycle progression.

27 December 2023

58

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

27 December 2023

60

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

63

61

5102

Wang H.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

27 December 2023

65

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

71

59

5412

Shaheen R.M.

1999

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

74

60

2178

Wood J.M.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

75

60

4819

Drevs J.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Integrin-Specific Activation of Rac Controls Progression through the G1 Phase of the Cell Cycle

27 December 2023

85

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

86

60

712

Erdreich-Epstein A.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

103

48

151

MacDonald T.J.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist

27 December 2023

109

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.

27 December 2023

114

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

148

57

1276

Ristimaki A.

1997

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

150

61

4375

Shono T.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

151

60

4926

Joki T.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000204

27 December 2023

Identifiers

0 references

1 reference